Ruti Aga's Six Years: One Forged Prescription, Three Failed Checks, and the Two Years Nobody Ever Asked For

On a March morning, on a road in a Chinese city, Ruti Aga won a half marathon. I have no split from that race, no finishing time, no field strength. What exists is a document — the Athletics Integrity Unit's statement, issued on Thursday, confirming methylprednisolone in the sample. And there is a second line in that statement that carries the entire weight of the case: the prescription for the knee treatment named a clinic that did not exist; the person who signed it was a family member, not a registered physician; and when questioned, that person claimed to have used "an old prescription pad from a former workplace" — which the clinic flatly disowned. Three checks, three failures. When I open a file like this, my first task is to break the sanction down, because the size of a sanction does not always describe the size of the offence. Here the arithmetic is simple: two years plus four equals six. But the question is not how six was built. The question is who wrote six where two would have done — and the answer sits in the prescription, not in the drug. Ruti Aga is 32. She won the 2026 Tokyo Marathon in 2:20:40. Before that, second at Berlin 2026 in 2:18:34. Three second places at World Marathon Majors in all — the layer of Ethiopian women's marathon that stands beside the title, never above it. I watched that 2026 Tokyo race from Delhi, on a screen, with a spreadsheet open in front of me. I was logging splits; I was not thinking that six years later the name would return in a file containing a knee injection and a forged prescription. What I saw that night was a settled, economical, unhurried run — the kind of race that decides which roads an athlete is invited to for the next three years. That is where the real conversation begins, and it is not about running. The first thing to correct is the drug class. The report that broke this case calls methylprednisolone a "prohibited steroid" and says WADA classifies it as performance enhancing. That is imprecise, and the imprecision is not minor — it files the entire case in the wrong drawer. Methylprednisolone is a glucocorticoid, WADA Prohibited List class S9, not an anabolic steroid (S1). And the critical condition of S9 is that it is prohibited in-competition only, and only by injection, oral or rectal route. A therapeutic knee injection, administered out of competition, is entirely legal. It becomes a violation only if residues are present in a sample taken in competition. That one sentence redraws the geography of the case. This is not a steroid case. It is a route-and-timing case. And timing here means the calendar, not morality: a road race's in-competition testing window opens at 23:59 the day before the race. A knee injection given days earlier lands inside that window. In plain terms, a legitimate treatment becomes a violation purely because of a date. Read the case again knowing that, and you find that Aga had a real defence available. She did not use it. She manufactured a document instead. The sanction arithmetic confirms it. Six years sounds strange in isolation, but broken into parts it is boringly standard. Two years for the presence violation — consistent with a Specified Substance finding where intent was not proven. Four years for tampering — the Code's standard sanction, not an exceptional action. Add them and you get six. That arithmetic tells us the panel rejected the no-significant-fault mitigation that would otherwise have reduced the presence sanction. The defence chose the route that lengthened the sentence. The ledger never closes; it only changes hands — and here it changed hands not from athlete to federation, but from the drug file to the document file. Now the question nobody asks. A 32-year-old marathoner with a bad knee, no team physician, no TUE infrastructure — what is she supposed to do? The East African road-running ecosystem answers that question with money, not medicine. Chronic knee pathology in distance running is not an accident; it is an occupational hazard, the load of 140–160 kilometres a week arriving directly at the joint. The cheapest, most available, fastest tool for masking that pain is a glucocorticoid injection. And when appearance fees are your primary income line, skipping a race is not merely skipping a race — it lowers your price in the next negotiation. I am not saying that makes a forged prescription acceptable. I am saying the forgery was born at a place where a medical need existed and no medical structure surrounded it. I went looking for a number and found a system wearing it. Note that the AIU statement needed inverted commas around the word "doctor." That alone tells the story. An athlete with a credentialed team physician keeps a record of the knee injection, updates location under the testing pool, and applies for a TUE or at minimum observes route-specific washout. None of that appears here. What appears is an unregistered relative, a clinic with no address, and a pad from a former workplace. This is not a filing error. It is the absence of a structure. A file remembers what a press release forgets. There is a dimension the headlines dropped. The four-year tampering sanction did not come from a document alone — it came from an interview, from statements made under questioning. That detail matters because language, translation and interview conditions are a recurring point of contention in East African road-running cases. An athlete answering in a third language, in a room without counsel, can turn an ambiguous sentence into "misleading information" without intending either. I am not claiming that happened here. I am saying that to understand a six-year ban you need to know that most of it came from a piece of paper and some of it from a sentence — and none of it from pharmacology. Then there is what survives. The violation is anchored to that March race, whose year the source does not state. Absent a finding of earlier use, results before that date are not automatically annulled. The 2026 Tokyo title stays in the record book, and so do the three Major second places. Respect, in my reading, passes through an audit — and the audit says: what was won then was won; what came later is a separate account. The same document contains what the statement leaves out and what is nonetheless nearly certain. The result and prize money from the competition where the sample was collected are ordinarily voided, along with ranking points accrued after that date. That is standard AIU procedure, not a special penalty. The article does not say so, but the probability is high. And that is where the literal and the financial weight of the sanction land together: a race won, its fee, its points, and every conversation that followed. Somewhere between the stopwatch and the spreadsheet, a career is decided. In this case the location is age 32. The six years run from 10 September, with provisional suspension counted from the same date — the source does not state the year, but the arithmetic is clear. The return age will be roughly 38. Look at the depth of Ethiopian women's marathon: where a 2:18 performer is not automatically selectable, no selector will have a reason to pick a 38-year-old with a doping record and two years away from racing. This is not a lifetime ban. It is a lifetime ban in practice, without the phrase being used. And the stage on which it happened is a story in itself. China's label road-race circuit is the thickest income band between Majors for East African marathoners — good appearance fees, low risk, light taping. It is also the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. That collision did not begin with Aga and will not end with her. The received story is that another runner has been caught. I do not accept that line, and the reason is pharmacological. Glucocorticoids have no proven endurance performance benefit. This is an anti-inflammatory. It dulls pain and may extend tolerance, in the way a painkiller does — by suppressing the signal rather than repairing anything. So a six-year sanction here is not about performance. It is about paperwork. And that is what the headlines are missing: the centre of the sport's integrity regime has shifted from detection to document verification. The AIU now reads prescriptions as closely as it reads samples. For an athlete with a real record, that is good news. For one with only a story, it is not. The second thing that bites is that the largest damage in this case was done not by a rule but by a media category. Calling this a steroid makes it easy, because the case can then be filed in a familiar drawer and no further thinking is required. But because this is an S9 matter, Aga had a legitimate defence available — route, timing, medical necessity. Had she produced genuine records, the presence sanction could have been argued down, possibly to a reprimand; and no tampering charge would have existed at all. With a TUE and correct washout, there would have been no case. She burned that route, and did it with a tool built in a house rather than a clinic. That is not cruelty; it is dishonesty — and dishonesty usually draws a longer sentence than an error, because it proves the athlete knew. The third point needs care. Hearing six years, it is easy to say enforcement against East African road runners is disproportionate. I will not go that far, because I hold only confirmed findings, not indignation. What can be said is this: two plus four is not anomalous anywhere; it is ordinary Code arithmetic. What is anomalous is how small the drug's role was and how large the document's role became. And that is why this case is bigger than one athlete's fate. Its real lesson is that if you compete clean, your most valuable asset is your medical record — and if you do not have it, you have nothing. Two March dates, one athlete, and the arithmetic in between. In the first March she wins a half marathon whose time nobody recorded. In the second, six years short of the road ahead, she would be looking for treatment for the knee that carried her to the first. I do not read the intervening years as exoneration. I read them as an account still to be reconciled. The next question is not whether Aga returns. The next question is who teaches the generation behind her that a knee injection is not the problem and a forged prescription is. The cost paid here is six years; the lesson being missed is that the distance between a legitimate treatment and a fake prescription is one register, one clinic, and one person entitled to sign. Athletics has spent crores on testing in the past decade and almost nothing on document literacy. Until that gap closes, this case will return in instalments — with another name, another glucocorticoid, and the same old prescription pad.